Stavudine: An update of its use in the treatment of HIV infection

Drugs

Volumn 58, Issue 5, 1999, Pages 919-949

  Hurst, Miriam ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS DNA; VIRUS RNA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; STAVUDINE;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032784006     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958050-00012     Document Type: Review

References (195)

1. Wei X, Ghosh SKJ, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 1995 Jan 12; 373: 117-22
2. Fauci AS. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996 Apr 1; 124 (7): 654-63
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998 Apr 24: 47 Suppl. RR-5: 43-83
4. Gazzard B, Moyle G. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998 Jul 25; 352: 314-6
5. Moyle GJ, Gazzard BG, Cooper DA. Antiretroviral therapy for HIV infection: A knowledge-based approach to drug selection and use. Drugs 1998 Mar; 55: 383-404
6. Lea AP, Faulds D. Stavudine: A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996 May; 51: 846-64
7. August EM, Birks EM, Prusoff WH. 3-Deoxythymidin-2-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol Pharmacol 1991 Feb; 39: 246-9
8. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2,3-didehydro-2,3-dideoxythymidine and 3-azido-2,3-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989 Apr 15; 264: 6127-33
9. Ho HT, Hitchcock MJM. Cellular pharmacology of 2,3-dideoxy-2,3-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989 Jun; 33: 844-9
10. Hoggard PG, Kewin S, Barry MG, et al. Effects of drugs on 2,3-dideoxy-2,3-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997 Jun; 41: 1231-6
11. Moyle GJ, Gazzard BG. The role of stavudine in the management of adults with HIV infection. Antiviral Therapy 1997 Dec; 2: 207-111
12. Huang P, Farquhar D, Plunkett W. Selective action of 2,3-didehydro-2,3-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 1992 Feb 5; 267: 2817-22
13. Yarchoan JA, Mitsuya H, Myers CE, et al. Clinical pharamacology of 3-azido-2,3-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989 Sep 14: 321: 726-38
14. Riddler SA, Anderson RE, Mellors JW. Antiretroviral activity of stavudine (2,3-didehydro-3-deoxythymidine, D4T). Antiviral Res 1995 Jun; 27: 189-203
15. Baba M, Pauwels R, Herdewijn P, et al. Both 2,3-dideoxythymidine and its 2,3-unsaturated derivative (2,3-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987 Jan 15; 142: 128-34
16. Balzarini J, Kang GJ, Dalai M, et al. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2,3-didehydro-2,3-dideoxyribonucleosides: A comparison with their parental 2,3-dideoxyribonucleosides. Mol Pharmacol 1987 Jul; 32: 162-7
17. Nakashima H, Pauwels R, Baba M, et al. Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds. J Virol Methods 1989 Dec; 26: 319-29
18. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Grantilocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3-azido-23-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989 Mar 1; 169: 933-51
19. Sørensen AM, Nielsen C, Mathiesen LR, et al. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993; 25: 365-71
20. + HcLa cells and a plaque assay in MT-4 cells. J Virol Methods 1990 Aug; 29: 197-208
21. Bridges EG, Dutschman GE, Gullen EA, et al. Favorable interaction of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996 Mar 22; 51: 731-6
22. Gao WY, Agharia R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2,3-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994 Apr 29; 269: 12633-8
23. Dutschman GE, Bridges EG, Liu S-H, et al. Metabolism of 2,3-dideoxy-2,3-didehydro β-L-(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D (+) nucleoside analogs in vitro. Antimicrob Agents Chemother 1996 Jun; 40: 1346-51
24. Deminie CA, Bechtold CM, Stock D, et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996 Jun; 40: 1346-51
25. Merrill DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency type I replication in vitro. J Infect Dis 1996; 173 (2): 353-64
26. Gao W-Y, Ahluwalia GS, Johns DG, et al. Mechanism of enhancement by thymidylate synthase inhibitors of AZT and D4T activities against HIV-1 replication [abstract no. 5]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1, Washington DC, 53
27. Gao W-Y, Tanaka M, Ahluwalia GS, et al. Suppression of both wild-type and drug-resistant HIV-1 by combination of thymidylate synthase inhibitors with AZT or D4T [abstract no. Mo.A. 1078]. 11th World AIDS Conference; 1996 Jul 7-12; Vancover, 68
28. Zhu Q-Y, Scarborough A, Polsky B, et al. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type I strains. AIDS Res Hum Retroviruses 1996 Apr 10; 12: 507-17
29. Veal GJ, Agrawal S, Byrn RA. Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antiviral Res 1998 Apr; 38: 63-73
30. Lantz O, Martinon F, Peguillet I, et al. Longitudinal analysis of the immune reconstitution after HAART (saquinavir-SGC, d4T and ddC) initiation in previously untreated patients (Mikado) [abstract no. 21123]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 263
31. Victorino R, Sousa A, Chares AP, et al. Effects of triple antiretroviral therapy on the expression of Fas antigen in patients with HIV1 infection [abstract no. 31178]. 12th World AIDS Conference; 1998 Jun 28 Jul 3; Geneva, 531
32. Gray C, Lawrence J, Schapiro J, et al. Dynamic changes in naive and activated T cells in blood and lymph nodes in patients receiving highly active antiretroviral therapy [abstract no. 269*/21112]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 261
33. Burgisser P, Hammann C, Kaufmann D, et al. Expression of CD28 and CD38 by CD8+ T cells in HIV infection correlates with viral load and CD4+ T cell number at baseline and during treatment [abstract no. 116*/31170]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 529
34. Nokta MA, Rossero R, Nichols J, et al. Partial immune restoration of HIV-infected patients on aggressive antiretroviral therapy (ddI, d4T and hydroxyurea, HU) [abstract no. 1-77]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sept 28-Oct 1; Toronto, 257
35. Nokta M, Rossero R, Loesch K, et al. Kinetics of tumor necrosis factor and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. AIDS Res Hum Retroviruses 1997 Dec 10; 13: 1633-8
36. Hagberg L, Svennerholm B, Gisslén M. Stavudine in combination therapies reduces cerebrospinal fluid HIV-I RNA levels to below detection limit during 3-9 months follow-up [abstract]. J Neurovirol 1998 Jun; 4: 353
37. Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cerebrospinal-fluid HIV-I RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998 May 23; 351: 1547-51
38. Thomas SA, Segal MB. The transport of the anti-HIV drug. 2,3-didehydro-3-deoxythymidine (D4T), across the bloodbrain and blood-cerebrospinal fluid barriers. Br J Pharmacol 1998 Sep; 125(1): 49-54
39. Arendt G, Giesen H-J, Jablonowski H. Stavudine stops neuroAIDS in AZT-non-responders [abstract no. 564]. 12th World AIDS Conference, 1998 Jun 28; Geneva, 562
40. Lin P-F, González CJ, Griffith B, et al. Stavudine resistance: An update on susceptibility following prolonged therapy. Antiviral Therapy 1999; 4(1): 7-20
41. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type I reverse transcriptase confers resistance to 2,3-didehydro-2,3-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994 Jun; 38: 1428-32
42. Salomon H, Montaner JSG, Belmonte A, et al. Diminished HIV-I sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase. Antiviral Therapy 1998; 3 (3); 177-82
43. Auger S, Ferre-Aubineau V, Monpeho S, et al. Genotypic analysis and phenotypic susceptibility of HIV-1 isolates from patients treated with stavudine (d4T)-didanosine (ddI) combination [abstract no. 77]. Antiviral Res 1998 Mar; 37: A61
44. Deminie CA, Bechtold CM, Riccardi K, et al. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy. AIDS 1998 Jan; 12: 110-2
45. Soriano V, Dietrich U, Villalba N, et al. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS 1997 Apr; 11: 696-7
46. Rusconi S, Milazzo L, Testa L, et al. Rapid onset of M184V mutation and phenotypic resistance to stavudine in zidovudine pre-treated HIV-1-infected individuals receiving the therapeutic regimens zidovudine plus lamivudine or stavudine plus lamivudine [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S23
47. Molguin A, Dietrich U, Immelmann A, et al. Genotypic and phenotypic resistance to stavudine after long-term monotherapy [abstract no. 32285]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 577
48. Danehower S, Castillo S, Keller A, et al. 1178M in HIV-1 is associated with in vitro d4T resistance and d4T failure in therapy-naïve pediatric subjects [abstract no. 474]. Clin Infect Dis 1998 Oct; 27 (4): 1011
49. Bossi P, Yvon A, Mouroux J-M, et al. Mutations in the human immunodeficiency virus type I reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages. Res Virol 1998 Nov-Dec; 149: 355-61
50. Jackson CR, Vavro C, DiLiberti JH, et al. Stavudine (D4T, Zeril Rm) sensitivities in clinical HIV isolates obtained from a pediatric population [abstract]. Pediatr Res 1996 Apr; 39: 174, Part2
51. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences USA 1995 Mar; 92: 2398-402
52. Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type I reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999 Aug; 43 (8): 1961-7
53. Loveday C, Devereux H, Huckett L, et al. High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999 Apr 1; 13: 627-8
54. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse trancriptase gene of human immunodeficiency virus type I confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998 Nov 15; 102 (10): 1769-75
55. Holguin A, Dietrich U, Immelmann A, et al. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. Antiviral Therapy 1998; 3 (3): 183-6
56. Ross LL, Johnson M, Hernandez J, et al. D4T-based combination therapy selects for "ZDV like" HIV-I resistance mutations in ZDV-naive adult patients [abstract no.145]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1999 Sep 26-29; San Francisco
57. 184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998 May 7; 12: 705-12
58. Zhu Z, Hitchcock MJ, Sommadossi JP. Metabolism and DNA interaction of 2,3-didehydro-2,3-dideoxythymidine in human bone marrow cells. Mol Pharmacol 1991 Nov; 40: 838-45
59. Chen C-H, Vazquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991 May; 39: 625-8
60. Faraj A, Fowler DA, Bridges EG, et al. Effects of 2,3-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994 May; 38: 924-30
61. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992 Sep; 166: 480-5
62. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39 (10): 2309-15
63. Kaul S, Mummaneni V, Barbhaiya RH. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: Application to bioequivalence assessment of various capsule formulations. Biopharm Drug Dispos 1995 Mar; 16: 125-36
64. Seifert RD, Stewart MB, Sramek IJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994 Nov; 38: 405-10
65. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 1997 Oct; 33: 276-84
66. Kim GP, Brett-Smith H, Friedland G, et al. Anti-HIV effect, toxicity, and pharmacokinetics of 23-didehydro-3-deoxythymidine (D4T) at low/moderate doses [abstract no. 561]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy: 1992 Oct 11-14; Anaheim, 204
67. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 1994; 38: 1-4
68. Unadkat JD, Keller RD, Nosbisch C, et al. Maternal - Fetal transfer of 2,3-didehydro - 3 deonythymidine (D4T) [abstract]. Pharm Res 1994 Oct; II Suppl.: S-451
69. Hoggard P, Khoo S, Barry M, et al. Intracellular metabolism of zidovudine and stavudine in combination [letter]. J Infect Dis 1996 Sep; 174: 671-2
70. Zhu Z, Ho H-T, Hitchcock MJ, et al. Cellular pharmacology of 2,3-didehydro-2,3-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol 1990 May 1; 39: R15-9
71. Kaul S, Christofalo B, Raymond RH, et al. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemothor 1998 Sep; 42: 2295-8
72. Zerit(TM) (stavudine) capsules. Product Information Sheet, Bristol-Myers Squibb, Princeton, New Jersey, US, Jun 1994
73. Taylor S, Drake SM, White DJ, et al. The impact of ritonavir/saquinavir/stavudine on viral load in seminal fluid and plasma compartments [abstract no. 23397]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 421
74. Zhang H, Dornadulla G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998 Dec 17; 339: 1803-9
75. Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999 Jun; 28: 1252-9
76. Haworth SJ, Christofalo B, Anderson RD, et al. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndrom Hum Retrovirol 1998 Mar 1; 17: 235-8
77. Straube E, Kuhlmann BK, Weimann MW, et al. Stavudine penetrates the blood-brain barrier [abstract no. 12354]. 12th World AIDS Conference; 1998 Jun 28-Jul 3: Geneva, 84
78. Brady K, Aldrich J, Broston R, et al. Stavudine entry into cerebrospinal fluid of HIV-infected subjects after single and multiple doses [abstract no. 12355]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 84
79. Munch-Petersen B, Cloos L, Tyrsted G, et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991 May 15; 266: 9032-8
80. De Clereq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992 Feb; 8: 119-34
81. McGuigan C, Tsang H-W, Sutton PW, et al. Synthesis and antiHIV activity of some novel chain-extended phosphoramidale derivatives of d4T (stavudine): Esterase hydrolysis as a rapid predictive test for antiviral potency. Antiviral Chem Chemother 1998 Mar; 9: 109-15
82. Meier C, Lorey M, De Clerq E, et al. cycloSal-2,3-dideoxy-2,3-didehydrothymidine monophosphate (cycloSal-d4TMP): Synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 1998; 41 (9): 1417-27
83. Sommadossi JR, Kidd LH, McClure HM, et al. In vitro and in vivo disposition and metabolism of 2,3-didehydro-2,3-dideoxythymidine (D4T) [abstract no. PO-A25-0582]. 9th International Conference on AIDS; 1993 Jun 6-11; Berlin, 231
84. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleo sides: Report of two randomized trials (ACTG 290 and 298) [abstract no. 2]. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5, 1998; Chicago
85. Katlama C, Valantin M-A, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-I infection. Ann Intern Med 1998 Oct 1; 129: 525-31
86. Sommadossi J-P, Valantin MA, Zhou X-J, et al. Intracellular phosphorylation of stavudine (D4T) and 3TC correlated with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients [abstract no. 362]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
87. Gallant JE, Chaisson RE, Keruly JC, et al. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. AIDS 1999; 13 (2): 225-9
88. Piscitelli SC, Kelly G, Walker RE, et al. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999 Mar; 43 (3): 647-50
89. Grasela D, Christofaleo B, Raymod R, et al. Safety and pharmacokinetics (PK) of stavudine (d4T) in subjects with mild, moderate or severe renal impairment [abstract no. 490]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29-Feb 2; Washington, DC. 145
90. Schaad HJ, Petty BG, Grasela DM, et al. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrob Agents Chemother 1997 Dec; 41: 2793-6
91. Federici ME, Kline MW, Rulkiewicz VL, et al. A phase I/II evaluation ol'stavudine (d4T) in children with HIV infection. In: Antiviral News 1996 Aug; 4: 109-11
92. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: Pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996 Jun; 97 (Pt 1): 886-90
93. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society USA Panel. JAMA 1998 Jul 1; 280: 78-86
94. Bartlett JG. IDCP guidelines: Management of HIV infection. Infect Dis Clin Pract 1997 Sep-Oct; 6: 422-9
95. De Cock KM. Guidelines for managing HIV infection: The goal is maximal suppression of HIV replication for as long as possible. BMJ 1997 Jul 5; 315: 1-2
96. British HIV Association. British HIV Association (BHIVA) Guidelines for the Treatment of HIV Disease with Antiretroviral Therapy. April 1999. Consultation draft number 2: 30/4/99. Available on http://hivinsite.uesf.edu
97. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis 1995 Mar; 171 Suppl. 2:S123-130
98. Browne MJ, Mayer KH, Chafee SBD, et al. 2,3-Didehydro 3 deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. J Infect Dis 1993 Jan; 167: 21-9
99. Gottlieb M, Peterson D, Adler M, et al. Comparison of safety and efficacy of two doses of stavudine (Zerit, d4T) in a large simple trial in the LIS Parallel Track Program [abstract no. 1171]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995, Sep 17-20; San Francisco. 235
100. Peterson EA, Ramírez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995 Mar; 171 Suppl. 2: S131-139
101. Stavudine (Zerit(TM)), also known as d4T. Final Results of the Study BMS-019 (A1455-019) Phase III Comparative Trial. Bristol-Myers Squibb Company, Princeton, New Jersey, USA. 1995
102. Molina J-M, Chene G, Ferchal F, et al. The ALB1 trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. J Infect Dis 1999; 180: 315-58
103. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54
104. + lymphocyte count predict both response to antiviral therapy and therapeutic failure. Ann Intern Med 1997 Jun 15; 126 (12): 939-45
105. Mellors JW, Rinaldo Jr CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by life quantity of virus in plasma. Science 1996 May 24; 272: 1167-70
106. Katlama C, Murphy R, Johnson V, et al. The Atlantic study; a randomised open-label study comparing two protease-inhibitors (PI)-sparing antiviral strategies versus a standard PI-containing regimen [abstract no. 18]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago
107. Carr A, Hudson J, Hoy J, et al. Ozcombo I: control of HIV replication in treatment naive patients in a randomised trial of HAART [poster no. 633]. Report from the 6th Conference on Retroviruses and Oppurtunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999 Jan 31-Feb 4; Chicago (IL.). (Data on file)
108. Katlama C, Calves V, Pellegrin JL, et al. MIKADO: saquinavir soft gel capsule in combination with D4T/DDC [abstract no. 12244]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 60
109. Florence E, Colehunders R, Vandeream B, et al. A randomised clinical trial comparing a ritonavir/saquinavir (RTV-SQV) versus an indinavir (IDV) containing triple therapy regimen (Iris Study) [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S34
110. Saimot AG, Landman R, Damond F, et al. Stavudine (d4T), didanosine (ddI) and ritonavir as a triple therapy in antiretroviral-naive patients: Results at 72 weeks [abstract no. 22401]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 344
111. Eron J, Peterson D, Murphy R, et al. An open-label, randomized, comparative study of d4T + ddI + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients (START II) [abstract no. 12225]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 56
112. Thompson M, Roberts A, Wheat LJ, et al. Randomized study of adefovir dipivoxil (ADV) in combination with indinavir (IDV) and reverse transcriptase inhibitors for treatment-naive HIV-infected patients [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S76
113. Gulick R, Squires K, Powderly W, et al. An open-label, randomized, comparative study of d4T + 3TC + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients (START I) [abstract no. 12223]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 56
114. Raffi F, Reliquet V, Francois C, et al. Stavudine didanosinenevirapine: A convenient highly active triple combination for first line antiretroviral therapy [abstract no. 12239]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 59
115. Raffi F, Reliquet V, Hascoel C, et al. The VIRGO trial: d4T/ddI (qd)/nevirapine (bid or qd) in antiretroviral-naïve HIV I-infected patients - A convenient and potent regimen [poster no. 632]. Report from the 6th Conference on Retroviruses and Opportunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999 Jan 31-Feb 4; Chicago (IL). (Data on file)
116. Garcia F, Knobel H, Sambeat MA, et al. An open randomised study comparing d4T plus ddI and nevirapine (QD) versus d4T plus ddI and nevirapine (BID) in antiretroviral naive chronic HIV-I infected patients in very early stages (Spanish Scan Study) [Poster no. 628]. Report from the 6th Conference on Retroviruses and Opportunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999 Jan 31-Feb 4; Chicago (IL). (Data on file)
117. Data show that new HIV/AIDS drug, Sustiva (TM) (efavirenz), effective in combination with d4T and 3TC - Sustiva combination suppressed HIV in central nervous system and female <>, Dupont Pharmaceuticals, www.dupont.com. 23 Mar 1999
118. Murphy R, Katlama C, Johnson V, et al. The Atlantic Study: a randomised open-label study comparing two protease inhibitor (PI) sparing antiretroviral strategies versus a standard PIcontaining regimen; 48 week data [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-29, Moscone Center, California; 1999
119. START II. Bristol Myers Squibb; 1999. [Data on file]
120. Boukli N, Meyohas MC, Picard O, et al. Virological follow-up of HIV infected patients treated by a triple combination therapy with protease inhibitor [abstract no. 12297]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 72
121. Hogg RS, Montaner JSG, Christopherson C, et al. Antiviral effect of AZT versus D4T in combination with 3TC and indinavir in the context of a population-based study [abstract no. 42169]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 806
122. Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of BID firstline ritonavir/indinavir plus double nucleoside combination therapy in HIV infected individuals [poster no. 631]. Report from the 6th Conference on Retrosviruses and Opportunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999, Jan 31-Feb 4; Chicago (IL). (Data on file)
123. Workman C, Musson R, Dyer W, et al. Novel double protease combinations-combining indinavir (IDV) with ritonavir (RTV): Results from first study [abstract no. 22372]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 338
124. Reijers MHE, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998 Jul 18; 352: 185-90
125. Tural C, Clotel R, Romeu J, et al. Double (3tc + d41) vs triple0 (3tc + d4t + suquinavir) therapy in HIV-1 experienced patients (ZDV + ddC/ddl) with a low baseline HIV-1 viral load (median 4089 copies/ml) [abstract no. 22344]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 332
126. Villalba N, Gómez-Cano M, Casas E. Safety and efficacy of two different triple drug combinations in which either lamivudine or didamosine were administered with stavudine plus indinavir. AIDS 1997 Dec; 11; 1896-7
127. Battegay M, Bernasconi E, Flepp M, et al. A pilot study of saquinavir in combination with ritonavir and d4T in patients with advanced HIV disease [abstract no. 1-203]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 281
128. Hengge U, Brockmeyer NH, Exner V, et al. Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in pretreated HIV-patients: Antiviral effect and safety in an ongoing study [abstract no. 122261. 12th World AIDS Conference: 1998 Jun 28-Jul 3; Geneva, 56
129. Maggiolo F, d'Arminio Monforte A, Testa L,. et al. Rescue therapy with stavudine, nelfinavir and efavirenz: Preliminary results [abstract] AIDS 1998 Nov: 12 Suppl. 4: S47
130. Roca B, Minguez C, Andrés J, et al. Stavudine, lamivudine, and indinavir in non-naive HIV-infected patients [abstract no. Pt 16]. AIDS 1998 Nov; 12 Suppl. 4: S45
131. Vernazza P, Battegay M, Bernasconi F, et al. Virologic long term results of a double protease inhibilor therapy with saquinavir and ritonavir plus stavudine [abstract no. 12313]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 75
132. Skowron G, Leoung G, Yen-Lie BB, et al. Stavudine (d4T), nelfinavir (NFV) and nevitapine (NVP): Suppression of HIV-I RNA to fewer than 50 copies/ml during 5 months of therapy [abstract no, 12275]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 67
133. Santin M, Consiglio E, Podzarmczer D, et al. Preliminary data of a pilot study comparing two protease inhibitor regimens (d4T + 3TC + IDV vs d4T + RTV + SQV) in pre-treated patients [abstract no. 60791]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 1146
134. Petrak RM, Boyer N, Hines D, et al. A study to evaluate the clinical and virologic efficacy of a Crixivan, ddI, and d4T combination [abstract]. Clin Infect Dis 1997 Aug; 25: 395
135. Pedneault L, Elion R, Adler M, et al. A pilot study of safety and antiviral activity of the combination of stavudine, didanosine and nelfinavir in HIV-infected subjects [abstract]. AIDS 1996 Nov; 10 Suppl. 2: S17
136. Bosco O, Fibhia GC, Gomma M, et al. Triple therapy with three nucleoside reverse transcriptase inhibitors: Good control of HIV-I viral replication [abstract no. P545]. Clin Microbiol Infect 1999; 5 (Mar) Suppl. 3.
137. 3 [abstract no. 22403]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 345
138. Truchis P, Zucman D, Dupont C, et al. Long-term follow-up of a cohort of 144 nucleosides-experienced patients treated with D4T + 3TC + indinavir (IDV) [abstract no. 60875]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 1160
139. Sherer R, Jasek J, Maclean M. Ritonavir + saquinavir + 2 NRTIs as first line HAART therapy: 21 patients from Cook County Hospital, Chicago [abstract no. 60619]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 1114
140. Farnsworth A, Squires K, Currier JS, et al. Women first; a study of the effects or treatment in women + HIV-infected with combination nelfinavir, saquinavir, stavudine, and lamivudine [abstract no. 12305]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 74
141. Barbour C. Long term viral suppression using quadruple drug combination therapy in treatment experienced HIV/AIDS patients, following initial protease failure [abstract no. 322951. 12th World AIDS Conference; Jun 28; Geneva, 579
142. Rodriguez-Rosado R, Soriano V, Jimenez I, et al. Efficacy and safety of the combination of ritonavir plus saquinavir, with two nucleoside analogues [abstract no. 12336]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva. 80
143. Henry K, Kane E, Melroe H, et al. Experience with a ritonavir/saquinavir based regiment for the treatment of HIV-infection in subjects developing increased viral loads while receiving nelfinavir [abstract no. 1-204]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 282
144. De Wit S, Cassano P, Hermans P et al. Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudinelamivudine. AIDS 1990; 13 (7): 864-5
145. Murphy RL, Gulick R, Smeaton L, et al. Treatment with indinavir, nevirapine, stavudine, and 3TC following therapy with an amprenavir-containing regimen [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S9
146. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type I replication. Science 1994; 266: 801-5
147. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 1998 May 28; 12: F71-7
148. Jaegel-Guedes E, Wolf E, Goeppner S, et al. D4T/ddl plus hydroxyurca: An alternative to a PI containing triple regimen in ART-naive HIV+ patients? [abstract no. 3231.5]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 583
149. Miles S, Winters RE, Ruane P, Salvage of multi-drug resistant HIV infection with D4T/3TC/hydroxyurea [abstract no. 288*/12205]. 12th World AIDS Conference; 1998 Jun 28-JuI 3; Geneva, 52
150. Grunke M, Dechant C, Löw P, et al. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection [letter]. J Acquir Immune Defic Syndr 1999 Aug 15; 21 (5): 424-6
151. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998 Apr 17; 47 Suppl. RR-4: 1-31
152. Funk MB, Linde R, Wintergerst U, et al. Viral load and CD4-cell count under a triple-therapy with nelfinavir and two RT-inhibitors in previously untreated HIV-infected children [abstract no. 12256]. 12th World AIDS Conference 1998 Jun 28-Jul 3; Geneva, 63
153. Kline M, Fletcher CV, Brundage RC, et al. Combination therapy with saquinavir soft gelatin capsules plus nucleoside antiretroviral agents in HIV-infected children [abstract no. 12260]. 12th World AIDS
154. Monpoux F, Sirvent. Sirveni N, Cottalorda J, et al. Stavudine., lamivudine and indinavir in children with advanced HIV-I infection: Preliminary experience. AIDS 1997 Oct; II: 1523-5
155. Wintergerst U, Hoffman F, Sölder B, et al. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatr Infect Pediatr Infect Dis J 1998 Jun; 17: 495-9
156. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998 Mar; 132: 543-6
157. Scherphier HJ, Roos MTL, Pakker NG, et al. Combination therapy with nelfinavir, stavudine and lamivudine (HAART) in HIV-I infected children: Kinetics of immune reconstitution [abstract no. 22362]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 336
158. Kline MW, Van Dyke RB, Lindsey JC. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. Pediatrics 1998 Feb; 101: 214-20
159. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverseeffects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998; 12 (14): 1735-44
160. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Medic 1995 May; 1 (5): 417-22
161. Honkoop P, Scholte HR, de Man RA, et al. Mitchondrial injury: Lessons from the fialuridine trial. Drug Saf 1997 Jul; 17 (1): 1-7
162. Lewis W, Dalakos MC. Mitochondrial toxicity of antiviral drugs. Nat Medic 1995; 1 (5): 417-22
163. Spotswood L, Spruance SL, Pavia AT. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: A randomized, double-blind, controlled trial. Ann Intern Med 1997 Mar 1; 126: 355-63
164. Duncan KM, Coleman RL, Kapusnik-Uner JE. Stavudine: Efficacy and tolerability - Comparison of the parallel track trial to literature. J Infect Dis Pharmacother 1996; 2 (1): 29-44
165. Ahmad S, Sukthankar A, Stavudine induced macrocytosis [letter]. Genitourin Med 1997 Oct; 73: 421
166. Martin GJ, Blazes DL, Mayers DL, et al. Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection. Clin Infect Dis 1999 Aug; 29: 459-60
167. Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995 Sep; 90 (9): 1433-6
168. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet 1999 Mar 13; 353 (9156): 1-2
169. Schiano TD, Lissoos TW, Ahmed A, et al. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol 1997 Sep; 92: 1563-4
170. Ziol M, Ganne-Carrié N, Christidis C, et al. Non alcoholic steatohepatitis in HIV and HCV infected patients treated by antiretroviral tritherapy. J Hepatol 1999; 30 Suppl. 1: 239
171. Lenzo NP, Garas BA, French MA. Hepatitic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report. AIDS 1997; 11 (10): 1294-6
172. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-I infection. Lancet 1998 Mar 21; 351: 867-70
173. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipoatrophy) in patients receiving a nucleoside analogue therapy including D4T [poster no. 653]. Report from the 6th Conference on Retroviruses and Opportunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999 Jan 31-Feb 4; Chicago (IL). (Data on file)
174. Madge S, Kinloch S, Tyrer M, et al. Lipodystrophy syndrome (LS) in patients on reverse transriptase inhibitors [poster no. 654]. Report from the 6th Conference on Retroviruses and Opportunistic Infections. Selected Posters. Prepared by BMS Global Marketing; 1999 Jan 31-Feb 4; Chicago (IL). (Data on file)
175. Melbourne KM, Brown SL, Silverblatt FJ, Gynecomastia with stavudine treatment in an HIV-positive patient Ann Pharmacother 1998 Oct; 32: 1108
176. Nieuwkerk P, Gisolf EH, Van Leeuwen R, et al. Impact of ritonavir/saquinavir versus ritonavir/saquinavir/stavudine on patients' health-related quality of life: preliminary results [abstract no. 14338]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 250
177. Petersen A, Johnson M. Long-term comparison of BID and TID dosing Viracept (nelfinavir) in combination with stavudine (d4T) and lamivudine (3TC) in HIV patients [abstract no. 12224]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 56
178. Pascucci R, Wolf E, Virgin G, et al. Community based observations support virostatic efficacy of D4T in advanced HIV patients [abstract no. We.B, 3120]. 11th World AIDS Conference; 1996 Jul 7-12; Vancouver, 76
179. Landman R, Damond F, Mathez D, et al. Stavudine (d4T), Didanosine (ddI) and Ritonavir as a Triple Therapy in Antiretroviral-naive Patients; Results at 72 Weeks. Poster presentation. (Data on file)
180. Jimenez-Nacher I, Rodriguez-Rosado R, Anton P, et al. Virological failure and adherence to antiretroviral therapy in HIV-infected patients [abstract no. 32350]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 591
181. Nguyen DT, Ripouteau C, Fievet M-H, et al. Compliance in the combination of two nucleoside analogues plus protease inhibitor treatment in persons with human immunodeficiency virus infection [abstract no. 83.014]. 8th International Congress on Infectious Diseases; 1998 May 15-18; Boston, 239
182. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Paediatric HIV Infection. Developed by the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Available at http://hivinsite.ucsf.edu
183. Product news in brief: BMS launches oral Zerit for HIV-infected children in US. Scrip 1997 Jan 28 (2201): 20
184. United Nations Joint Commission on AIDS (UNAIDS). Report on the Global HIV/AIDS Epidemic (1998) [online]. Available from: URL: http://hivinsite.ucsf.edu/social/un/2098.3cc0.html
185. Levy, JA. HIV research: A need to focus on the right target. Lancet 1995 Jun 24; 345: 1619-21
186. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-98
187. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996 Aug; 52: 168-85
188. Aboulker J-P. The place of the protease inhibitors in antiretroviral combination therapy. Curr Opin Infect Dis 1996 Feb; 9: 19-22
189. Weidle PJ, Mhidde E, Djomand G, et al. Relevance of AIDS treatment with two nucleoside analogues alone [letter]. Lancet 1999 Jun 12; 353: 1989-90
190. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-I syneytium-inducing phenotype for rate of CD4' depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8
191. D'Aquila R, Johnson V, Welles SL, et al. Zidovudine resistance and HIV-I disease progression during antiretroviral therapy. Ann Intern Med 1995 Mar 15; 122 (6): 401-8
192. Decks SG, Volberding P. The AIDS Knowledge Base: Antiretroviral Therapy for HIV Disease. 1999 edition. Available from http://hivinsite.ucsf.edu
193. Perry CM, Faulds D. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997 Apr; 53: 657-80
194. Foster RH, Faulds D. Abacavir. Drugs 1998 May; 55: 729-36
195. Noble S, Goa KL. Adefovir dipivoxil. Drugs 1999 Sep; 58 (3): 479-87